Study of Undertreatment of Patients With Dyslipidemia in Bulgaria (CEPHEUS)

AstraZeneca

Status: Completed

Conditions: Dyslipidemia

Study type: Observational

Funder types: Industry

Identifiers

NCT01075594

NIS-CBG-CRE-2009/1

Details and patient eligibility

About

The purpose of this study is to establish the proportion of Bulgarian patients on lipid-lowering pharmacological treatment reaching the LDL-C goals according to the Fourth Joint European Task Force guidelines.

Enrollment: 2,500 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Lipid lowering drug treatment for at least 3 months, with no dose change for a minimum of 6 weeks
• Signed Informed Consent

Exclusion criteria

• Informed Consent not provided

Trial design

2,500 participants in 1 patient group

1

Description:

Patients with dyslipidemia on lipid lowering therapy